The global clinical study of PADN technology in treating Pulmonary Hypertension Associated with Left Heart Disease was successfully conducted in Portugal, Singapore, and Malaysia, with the first enrollment.

"Chinese Expert Consensus on Percutaneous Pulmonary Artery Denervation for Pulmonary Arterial Hypertension (PADN)" was officially released.

The world's first post-market PADN procedure was successfully performed at the Xiamen Cardiovascular Hospital Xiamen University.

PADN obtained the U.S. Medicare coverage code by Center for Medicare&Medicaid Services(CMS) approval.

PADN was obtained by China’s National Medical Products Administration(NMPA) approval.

PADN was obtained as the FDA Humanitarian Use Device (HUD) designation.

PADN-PH-HF clinical trial had been launched in domestic multiple clinical centers and the first patients enrollment.

Pulnovo Medical completed a multi-million dollar equity financing round through Yuanbio Venture Capital, OrbiMed Healthcare Fund Management, Cenova Capital, Lilly Asia Ventures(LAV), GaoRong Capital，HuiHe Capital and GC&H Investments.

Pulnovo Medical announced results from PADN-CFDA clinical trial for the treatment of Pulmonary Arterial Hypertension (PAH).

PADN had been included in 2022 ESC/ERS guidelines for the diagnosis and treatment of PH.

PADN-CFDA clinical trial had completed all patients enrollment.